- Revenue Cycle Management
- COVID-19
- Reimbursement
- Diabetes Awareness Month
- Risk Management
- Patient Retention
- Staffing
- Medical Economics® 100th Anniversary
- Coding and documentation
- Business of Endocrinology
- Telehealth
- Physicians Financial News
- Cybersecurity
- Cardiovascular Clinical Consult
- Locum Tenens, brought to you by LocumLife®
- Weight Management
- Business of Women's Health
- Practice Efficiency
- Finance and Wealth
- EHRs
- Remote Patient Monitoring
- Sponsored Webinars
- Medical Technology
- Billing and collections
- Acute Pain Management
- Exclusive Content
- Value-based Care
- Business of Pediatrics
- Concierge Medicine 2.0 by Castle Connolly Private Health Partners
- Practice Growth
- Concierge Medicine
- Business of Cardiology
- Implementing the Topcon Ocular Telehealth Platform
- Malpractice
- Influenza
- Sexual Health
- Chronic Conditions
- Technology
- Legal and Policy
- Money
- Opinion
- Vaccines
- Practice Management
- Patient Relations
- Careers
Study: U.S. cancer patients live longer than those in Europe
The United States spends more on cancer care than European countries, but its patients typically live nearly 2 years longer, according to a study in the April issue of Health Affairs.
The United States spends more on cancer care than European countries, but its patients typically live nearly 2 years longer, according to a study in the April issue of Health Affairs.
Researchers found that the cost of cancer treatment in the United States was higher than the same care in 10 European countries from 1983 to 1999, but that patients in whom cancer was diagnosed during 1995 to 1999 lived an average of 11.1 years after diagnosis in the United States, compared with 9.3 years in Europe.
To determine whether the added longevity was worth the cost, researchers applied the standard metrics for valuing additional years of life in dollar terms. They found that the extra years were worth an an average of $61,000 for an individual cancer patient.
